Survival advantage seen for A+ADV in advanced Hodgkin lymphoma

14 July 2022

ABVD (hazard ratio for disease progression or death, 0.68). Subsequent therapy, including transplantation, was received by fewer patients in the A+AVD versus the ABVD group, and fewer second cancers were reported in the A+AVD group (23 versus 32 patients). After an increased incidence of febrile neutropenia was observed with A+AVD, primary prophylaxis with granulocyte colony-stimulating factor was recommended.

"In this trial, treatment with A+AVD resulted in an improvement in both progression-free survival and overall survival," the authors write.

The study was funded by Takeda Development Center Americas and Seagen; Seagen manufactures brentuximab vedotin.


Copyright © 2022 HealthDay. All rights reserved.